![\"Doctor](\"https:\/\/www.newsbeep.com\/nz\/wp-content\/uploads\/2026\/02\/imaging-scans-16.9-1200x675.jpg\")
<\/p>\n<\/p>\n
Image source: Getty Images<\/p>\n
During earnings season, it’s not uncommon to see large share price swings as investors react to results. Unfortunately for two ASX healthcare shares, recent announcements sent their share prices tumbling.\u00a0<\/p>\n
Neuren Pharmaceuticals Ltd (ASX: NEU<\/a>) and Clarity Pharmaceuticals Ltd (ASX: CU6<\/a>) experienced share price declines yesterday of 10% and 4% respectively.\u00a0<\/p>\n Both ASX healthcare shares have had a tough past week.\u00a0<\/p>\n Does this create a buy low opportunity? Or is it going to be more of the same moving forward?<\/p>\n Let’s find out.\u00a0<\/p>\n Neuren Pharmaceuticals Ltd (ASX: NEU<\/a>) <\/p>\n Neuren Pharmaceuticals is a biopharmaceutical company specialising in developing new therapies for neurodevelopmental disorders that emerge in early childhood and are characterised by impaired connections and signalling between brain cells.<\/p>\n Its share price crashed almost 10% yesterday after news was released<\/a> that its partner, Acadia Pharmaceuticals Inc. (NASDAQ: ACAD<\/a>), received a negative trend vote<\/a> from Europe’s drug regulator for trofinetide, its treatment for Rett syndrome.<\/p>\n This dealt a potential blow to future revenue.\u00a0<\/p>\n While the drug is already approved in the US, Canada, and Israel, the uncertainty around European approval has investors selling, even though Acadia plans to appeal the decision.<\/p>\n For potential investors, the appeal process will certainly be worth monitoring, as it will directly impact future earnings.\u00a0<\/p>\n Its stock price is now down 15% in just the last 5 days of trading.\u00a0<\/p>\n Based on analyst ratings via TradingView, this could be a buy low opportunity for investors.\u00a0<\/p>\n Analysts ratings via TradingView have an average 12 month price target of $24.73 on this ASX healthcare stock.\u00a0<\/p>\n That indicates a massive upside of 69% from yesterday’s closing price of $14.63.\u00a0<\/p>\n However it doesn’t come without risk, pending the result of the company’s appeal.\u00a0<\/p>\n Clarity Pharmaceuticals Ltd (ASX: CU6<\/a>) <\/p>\n This ASX healthcare stock has also been on the decline in the past week following the release of its quarterly report<\/a>.<\/p>\n It is a clinical stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology<\/a>.<\/p>\n Clarity Pharmaceuticals shares fell 3.9% yesterday and are down more than 15% in the last week.\u00a0<\/p>\n After such a large fall in a short period of time, it could be a buy-low opportunity.\u00a0<\/p>\n This ASX healthcare stock closed trading yesterday at $2.96 per share.\u00a0<\/p>\n However the TradingView has an average analyst price target of $7.35.\u00a0<\/p>\n This indicates an upside of more than 148%.\u00a0<\/p>\n